Learn Why Podiatrists use Clarix for Wound Care

Developed by pioneers in the field of regenerative medicine, CLARIX cryopreserved umbilical cord allograft delivers the innate properties of amniotic tissue to facilitate the healing process across a range of surgical specialties.

With CLARIX, you’re able to transplant the innate biology to the surgical site, thus supporting a more structured healing environment, helping to manage regenerative healing, and facilitating your patient’s functional recovery.

  • Leap Into Functional Recovery

    Learn more about how Amniox is harnessing the unique power of human birth tissue through the CLARIX family of products by downloading the product brochure. Fill out the form below to receive a copy:
  • By clicking the button below, I declare that I am a licensed health care professional or staff member. I also agree to receive marketing communications from Amniox. I am aware that I can unsubscribe at any time.
  • This field is for validation purposes and should be left unchanged.

Regenerative Medicine, Backed by Research

Our extensive research allows us to preserve and deliver the most functional allograft for your needs.

600K

Transplants

380

Clinical Publications

35Y

Research & Development

Leap Into The Future of Functional Recovery with Clarix

Minimize risk of complications, including infection and amputation1-5,9

 

Our platform technology, HC-HA/PTX3, helps create a healing environment for wounds to achieve complete epithelialization for an overall healing rate of 87.5%6

Expedite functional recovery2-16 and accelerate wound healing

 

The Amniox family of cryopreserved umbilical cord allografts helps deliver the natural properties of human birth tissue to wound environments.1

Harness the natural properties of human birth tissue2 with
Clarix.

Learn more about the platform technology behind the CLARIX family of products by clicking the link below to download the product brochure.

Request More Information

Learn more about how our family of products can orchestrate regenerative healing which may improve patient outcomes. Fill out the form below and a representative will contact you.

By clicking the button below, I agree to receive marketing communications from BioTissue. I am aware that I can unsubscribe at any time.   Privacy Policy   Do Not Sell My Personal Information
This field is for validation purposes and should be left unchanged.
References
Tseng SC. Invest Ophthalmol Vis Sci. 2016;57(5):ORSFh1‐ORSFh8.
Caputo WJ, Vaquero C, Monterosa A, et al. Wound Repair Regen. 2016;24(5):885-893.
Couture M. Wounds. 2016;28(7):217-25.
Marston WA, Lantis JC 2nd, Wu SC, et al. Wound Repair Regen. 2019;27(6):680-86.
Marston WA, Lantis JC 2nd, Wu SC, et al. Wound Repair Regen. 2020. Online ahead of print.
Raphael A. J Wound Care. 2016;25(Sup7):S10-17.
Raphael A, Gonzales J. J Wound Care. 2017;26(Sup10):S38-44.
Cooke M, Tan EK, Mandrycky C, He H, O’Connell J, Tseng SC. J
Swan J. Surg Technol Int. 2014;25:73‐78.
Bemenderfer TB, Anderson RB, Odum SM, Davis WH. J Foot Ankle Surg. 2019;58(1):97-102.
DeMill SL, Granata JD, Berlet GC, et al. Surgical Technol Int. 2014;25:257-61.
Ellington J, Ferguson C. Surg Technol Int. 2014;25:63-67.
Garras D, Scott R. AOFAS Annual Meeting 2017.
Hanselman AE, Tidwell J, Santrock R. FootAnkle Int. 2015;Feb;36(2):151-8.
Stewart CM. SunKrist J Trauma Emerg Med Acute Care. 2019;1(1):1-6.
Warner M, Lasyone L. Surg Technol Int. 2014;25:251-5.